Researchers are closer to better diagnosing and treating age-related macular degeneration (AMD) after discovering new genetic signatures of the disease by reprogramming stem cells to generate high-resolution disease models. Read More
IFM Due has presented new stimulator of interferon genes protein (STING; TMEM173) antagonists reported to be useful for the treatment of cancer. Read More
The Ontario Institute for Cancer Research (OICR), the University of Toronto and Sinai Health System have divulged thienyl and cycloalkyl aminopyrimidine compounds acting as NUAK family SNF1-like kinase inhibitors reported to be useful for the treatment of cancer and fibrosis. Read More
Researchers from Alnylam Pharmaceuticals and collaborators published data from a study that aimed to identify novel therapeutic targets for abdominal obesity by searching for genetic variants associated with lower waist-to-hip ratio. Read More
Cellectis announced that the FDA has cleared its IND application to initiate a phase I/IIa clinical trial of UCART20x22 for patients with relapsed or refractory non-Hodgkin lymphoma (NHL). Read More
Sosei Group Corporation and AbbVie have entered a new drug discovery collaboration and option-to-license agreement to discover, develop and commercialize small molecules that modulate novel G protein-coupled receptor (GPCR) targets associated with neurological disease. Read More
Classic galactosemia (CG) is an inborn error of galactose metabolism caused by a severe deficiency of galactose-1-phosphate:uridylyltransferase (GALT) enzymatic activity, which leads to accumulation of several metabolites such as galactose-1-phosphate (Gal-1-P), the substrate of GALT, and galactonate and galactitol, the oxidation and reduction products. Read More
A study led by researchers at the Institut Curie and INSERM has identified a means of overcoming CD8+ T-cell exhaustion and loss of cytotoxic activity in tumors. Read More
